Bris­tol My­ers wins ap­proval for KRAS drug Kraza­ti in col­orec­tal can­cer

Bris­tol My­ers Squibb won ac­cel­er­at­ed ap­proval on Fri­day to take its KRAS in­hibitor to col­orec­tal can­cer pa­tients.

Kraza­ti will now be avail­able for use with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.